Kvantify’s Post

🔔 Neuralink Raises additional $43M 🔔 Elon Musk's Neuralink secures an additional $43M in Venture Capital funding from Peter Thiel's Founders Fund, bringing the total investment to $323M. 💸 The company is now valued at an impressive $5B post-private investments, as reported by Reuters. 🧠 Neuralink introduces the ‘Link’, a brain-computer interface (BCI) embedded with electrodes, seamlessly sewn into the brain's surface. This revolutionary device connects the brain to external electronics, paving the way for groundbreaking therapeutic applications. ⛑️ Musk envisions Neuralink's potential for treating conditions like blindness, paralysis, and depression. The Link's innovative design positions it as a game-changer in the field of neurotechnology. ✅ Following successful tests on monkeys and pigs, Neuralink received FDA approval for human clinical trials in May. The approval is big for the firm but many have been very sceptical at the potential damage that could be caused to the brain. 🌐 Venture capitalists are recognizing the immense post-FDA approval and growth to the valuation it could add. What do you think? #Neuralink #ElonMusk #Innovation #Neurotechnology #VentureCapital #technews

🚀 Exciting Funding News Alert! 🚀 QuantumDiamonds, our alumni of batch #12 successfully closed a €7M seed round, led by IQ Capital and Earlybird Venture Capital! 💎 QuantumDiamonds specializes in the creation of quantum sensors at the atomic scale, allowing for non-destructive, nano-scale imaging of magnetic fields. These sensors find applications in diverse industries such as semiconductor manufacturing and medical diagnostics. According to Kevin Berghoff, Co-Founder and CEO at QuantumDiamonds: “𝘞𝘦 𝘢𝘳𝘦 𝘢𝘵 𝘵𝘩𝘦 𝘧𝘰𝘳𝘦𝘧𝘳𝘰𝘯𝘵 𝘰𝘧 𝘳𝘦𝘷𝘰𝘭𝘶𝘵𝘪𝘰𝘯𝘪𝘴𝘪𝘯𝘨 𝘴𝘦𝘯𝘴𝘪𝘯𝘨 𝘵𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘺 𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘰𝘶𝘳 𝘸𝘰𝘳𝘬 𝘢𝘵 𝘘𝘶𝘢𝘯𝘵𝘶𝘮𝘋𝘪𝘢𝘮𝘰𝘯𝘥𝘴, 𝘢𝘥𝘷𝘢𝘯𝘤𝘪𝘯𝘨 𝘣𝘰𝘵𝘩 𝘴𝘦𝘮𝘪𝘤𝘰𝘯𝘥𝘶𝘤𝘵𝘰𝘳 𝘮𝘢𝘯𝘶𝘧𝘢𝘤𝘵𝘶𝘳𝘪𝘯𝘨 𝘢𝘯𝘥 𝘣𝘳𝘦𝘢𝘬𝘵𝘩𝘳𝘰𝘶𝘨𝘩𝘴 𝘪𝘯 𝘰𝘵𝘩𝘦𝘳 𝘤𝘳𝘪𝘵𝘪𝘤𝘢𝘭 𝘧𝘪𝘦𝘭𝘥𝘴 𝘴𝘶𝘤𝘩 𝘢𝘴 𝘣𝘪𝘰𝘭𝘰𝘨𝘺 𝘢𝘯𝘥 𝘤𝘩𝘦𝘮𝘪𝘴𝘵𝘳𝘺 𝘰𝘯 𝘢 𝘨𝘭𝘰𝘣𝘢𝘭 𝘴𝘤𝘢𝘭𝘦. 𝘛𝘩𝘦 𝘧𝘶𝘯𝘥𝘪𝘯𝘨 𝘸𝘪𝘭𝘭 𝘦𝘯𝘢𝘣𝘭𝘦 𝘶𝘴 𝘵𝘰 𝘮𝘰𝘷𝘦 𝘵𝘰𝘸𝘢𝘳𝘥𝘴 𝘵𝘩𝘦 𝘭𝘢𝘶𝘯𝘤𝘩 𝘰𝘧 𝘰𝘶𝘳 𝘧𝘪𝘳𝘴𝘵 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘱𝘳𝘰𝘥𝘶𝘤𝘵, 𝘴𝘶𝘱𝘱𝘰𝘳𝘵𝘦𝘥 𝘣𝘺 𝘵𝘩𝘦 𝘦𝘹𝘱𝘢𝘯𝘴𝘪𝘰𝘯 𝘰𝘧 𝘰𝘶𝘳 𝘲𝘶𝘢𝘯𝘵𝘶𝘮 𝘦𝘯𝘨𝘪𝘯𝘦𝘦𝘳𝘪𝘯𝘨 𝘵𝘦𝘢𝘮." IQ Capital, Earlybird, Onsight Ventures, First Momentum Ventures, Creator Fund, UnternehmerTUM, along with several angel investors from the semiconductor industry, have collectively contributed €3 million. Additionally, the European Innovation Council (EIC) Accelerator and the Bavarian state are extending €4 million in grant funding. Cheers to Kevin Berghoff (CEO), Kristina Liu (COO), and Fleming Bruckmaier (CTO) and your team for this remarkable achievement. Read more here: https://lnkd.in/dppMeNQ8

💸 With #QVCS, Maddyness UK profiles different #funds to give #founders and #entrepreneurs the information they need to choose the right #investor. Today, we speak to Dave Grimm, Partner at AlbionVC and UCL Technology Fund. "My #focus is on early-stage deeptech across the #physicalsciences and #engineering faculty at UCL. The areas I think are most interesting are #future of #compute, novel #AI and the #energytransition." "I’m looking for founders who understand that and are already falling in love with the #problem (not just obsessed with the #perfection of their #solution)." https://lnkd.in/evcdzfQH

🚀 We’re thrilled to announce that QpiAI has secured a pre-series A fundraise of US$ 6.5M led by YourNest Venture Capital and SIDBI Venture Capital Ltd. Our technology aims to enhance intelligence #modeling and intelligence #compute with the vertical integration of AI and Quantum Computing. With this capital, QpiAI will drive innovation in developing scalable quantum computers and advanced #AI platforms for sectors like pharmaceuticals, finance, materials, and manufacturing. Through integration of HPC built out of our lab infra and integration of all our Quantum and Gen-AI enabled platforms, we are uniquely positioned to offer full-stack quantum-HPC solutions and advance our customers’ needs in next-generation advanced computing. We thank all our investors for their confidence in QpiAI team and enabling us to start a new era in Indian deepetch. Cheers to team QpiAI! https://lnkd.in/gMVQSw_J #Quantum #QuantumComputing #HPC #Supercomputing #AI #Pharma #Materials #Manufacturing #Logistics #Datacenters #

Funding Update - What's happening in USA? - Biotech companies are getting massive funding #ObsidianTherapeutics secured a whopping $161M in a Series C financing round led by new investor Wellington Management. The Cambridge-based biotech company is advancing engineered cell and gene therapies to tackle cancer. #Flip, a social commerce startup, raised $144M in funding led by Streamlined Ventures, with a significant investment from AppLovin. Their innovative marketplace for video reviews is making waves in Los Angeles and beyond. #AlteromeTherapeutics scored $132M in a Series B round led by Goldman Sachs Alternatives. Their machine learning platform Kraken is driving the development of promising oncology therapies. #DiagonalTherapeutics emerged with $128M in a Series A round co-led by BVF Partners and Atlas Venture. They're on a mission to combat hereditary hemorrhagic telangiectasia, a challenging bleeding disorder. #Aerospike closed a hefty $109M investment led by Sumeru Equity Partners. The demand for their real-time NoSQL database management system is skyrocketing with the rise of AI applications. In addition to these, notable rounds include: - #AlsymEnergy: $78M led by Tata Limited and General Catalyst - #SiMa.ai: $70M led by Maverick Capital - #Torus: $67M led by Origin Ventures - #BinxHealth: $65M led by Hildred Capital - #Homebase: $60M led by L Catterton Growth And a special shoutout to Paris-based #Pigment, a business forecasting platform, which raised an impressive $145M in venture funding! Follow me to see more updates like this. #StartupFunding #VentureCapital #InnovationLeadership

The year 2023 marks a pivotal moment in the realm of #startupfunding, characterized by transformative #investmenttrends and evolving strategies. Here's an in-depth look at five critical trends reshaping this dynamic #investment landscape: 1. Adaptation in Capital Funding Amid Economic Shifts: In the shifting sands of 2023's economic landscape, Asimov, a Boston-based synthetic biology startup, emerged as a beacon of resilience and innovation. Amidst the tumult of #biotechfunding, Asimov's story began in 2017, founded by a team of visionaries determined to revolutionize cell and gene therapies. In a bold move, they secured a combined $200 million in Series A and Series B funding, a testament to their groundbreaking work in harnessing synthetic biology to manufacture core components of advanced therapies. This substantial #funding round, a significant feat in an #economy still recovering from the effects of peak #inflation, highlights Asimov's crucial role in bringing advanced therapies into the mainstream. Their journey, marked by strategic foresight and technological ingenuity, To read the full article, go to: https://lnkd.in/eD9G9wex

If you work on #techtransfer, #translationalresearch, or #innovation within an R&D institution like a university or a corporation, this blog post is for you. In this substack post, Venture Builder David Cohen-Tanugi presents an easy way to get a quick sense of your research colleagues so that you can be maximally effective going forward. #venturebuilding Plasma Science and Fusion Center at MIT

Are advances like AI for drug discovery, NGS, and CRISPR changing how funding in biotech works? How are these technologies altering who gets funding, what projects attract investment, and what are the implications? What can be learned from the software industry? Speed and scaling?

Danish Start-Up Kvantify Secures EUR 10 Million Seed Round 👏🏻 The company will use funds to strengthen its quantum computing leadership position, with an initial focus on developing applications for the life science sector. Read more here: https://lnkd.in/esfdpwzs #Quantum #Denmark #StartUp #LifeScience #QuantumComputing